Figure 4. Partial reversal of cardiovascular features by glibenclamide in Kir6.1^wt/VM mice.

(A) Summary of mean arterial pressure (MAP) in anesthetized placebo-implanted (Glib = 0) and approximately 19 mg/kg/day glibenclamide pellet–implanted WT and Kir6.1^wt/VM mice. (B) Summary of heart size (weight normalized to tibia length; HW/TL) for WT and Kir6.1^wt/VM mice implanted with either placebo pellets (Glib = 0) or pellets releasing approximately 19 mg/kg/day. For all figures, individual data points are represented as open circles, bars show mean ± SEM. Statistical significance was determined by 1-way ANOVA and post hoc Tukey’s test for pairwise comparison. **P < 0.01 from pairwise post hoc Tukey’s test.